BA/F3_EGFR DEL19激酶Kinase穩(wěn)定表達細胞株-BioVector NTCC保藏中心
I. Introduction
Cell Line Name：

BA/F3_EGFR-DEL19

Gene Synonyms:

Epidermal Growth Factor Receptor, ERBB1, EGFR

Host Cell:

Ba/F3

Stability: 16 passages
Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10% FBS

Mycoplasma Status:

Negative


II.Background
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors.


III. Representative Data
1. Anti-proliferation assay



Figure 3. Anti-proliferation assay of three reference compounds on the Ba/F3_EGFR-DEL19 Stable Cell Line


IV. Thawing

Thawing: Protocol
1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
4. Resuspend the cells in complete growth medium.
5. Add 10 ml of the cell suspension in a 10 cm dish.
6. Add promycin to a concentration of 1 μg/ml the following day.
Kinase細胞株



現(xiàn)代新藥研發(fā)的關(guān)鍵首先是尋找，確定和制備藥物作用靶點。在500多個已發(fā)現(xiàn)的藥物靶點里中，GPCR，Ion Channel，Kinase使用的最為廣泛。




激酶(kinase)是一類從高能供體分子（如ATP）轉(zhuǎn)移磷酸基團到特定靶分子（底物）的酶；這一過程謂之磷酸化。許多腫瘤的發(fā)生是由某些與生長相關(guān)的“激酶”發(fā)生突變導(dǎo)致異常活化引起的，因而針對這些突變激酶的抑制劑能夠有效抑制這些激酶的活性，從而達到抑制癌細胞增長的目的。
BioVector NTCC質(zhì)粒載體菌種細胞蛋白抗體基因保藏中心

電話：+86-010-53513060

網(wǎng)址：www.biovector.net